These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported||2005-004135-22||Multicenter phase II study with docetaxel, 5-FU, leucovorin, and oxaliplatin in patients with metastatic or locally advanced gastric cancer or cancer of the esophagogastric junction- FLOT||2008-08-31||due-trials|
|Ongoing||2006-006936-24||A multicenter, randomised phase II trial on the therapy of advanced gastric cancer or adenocarcinoma of the esophagogastric junction in patients older than 65 years with special regard on quality of l...||not-yet-due|
|Ongoing||2007-002828-15||An open-label, uncontrolled phase II trial of single agent sunitinib (SU 11248) for patients with chemo-refractory metastatic melanoma||not-yet-due|
|Not reported||2008-002197-35||Multizentrische randomisierte Phase II Studie zur Therapie des lokal fortgeschrittenen oder metastasierten NSCLC (Stadium IIIB/IV) mit Cisplatin/Docetaxel oder Oxaliplatin/Docetaxel||2011-11-23||due-trials|
|Ongoing||2009-018092-14||A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric carcinoma who have progressed after therapy with a fluoropyrimidine/plat...||not-yet-due|
|Ongoing||2010-018754-13||A randomized multicenter Phase II/III Study comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) versus Epirubicin, Cisplatin and 5-FU (ECF) in patients with locally advanced resectable adeno...||not-yet-due|
|Exempt Terminated||2011-003201-14||Phase I/II, Open Label, Dose Escalating Study To Investigate Safety, Tolerability, And Preliminary Efficacy Of The Trifunctional Anti-HER-2/neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-2/n...||not-yet-due|
|Completed, but no date||2014-002665-30||Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric juncti...||bad-data|